Medicus Pharma Ltd. (NASDAQ:MDCX - Free Report) - Analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for Medicus Pharma in a research note issued on Tuesday, April 8th. Brookline Capital Management analyst K. Raja expects that the company will post earnings of ($0.23) per share for the quarter. Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Medicus Pharma's current full-year earnings is ($1.14) per share. Brookline Capital Management also issued estimates for Medicus Pharma's Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.23) EPS and FY2029 earnings at $1.68 EPS.
Medicus Pharma (NASDAQ:MDCX - Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14.
A number of other equities research analysts also recently commented on MDCX. Maxim Group assumed coverage on Medicus Pharma in a research report on Tuesday, December 17th. They issued a "buy" rating and a $10.00 target price on the stock. D. Boral Capital started coverage on Medicus Pharma in a research note on Monday. They issued a "buy" rating and a $14.00 price objective on the stock. Finally, D Boral Capital upgraded Medicus Pharma to a "strong-buy" rating in a research report on Monday.
Get Our Latest Stock Report on MDCX
Medicus Pharma Stock Performance
Shares of MDCX stock traded up $0.09 during mid-day trading on Thursday, hitting $3.70. The company had a trading volume of 18,671 shares, compared to its average volume of 50,325. The company has a 50 day simple moving average of $3.46. Medicus Pharma has a 52-week low of $1.80 and a 52-week high of $6.00.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC purchased a new position in Medicus Pharma Ltd. (NASDAQ:MDCX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,457,165 shares of the company's stock, valued at approximately $3,628,000. Medicus Pharma comprises approximately 1.3% of Interchange Capital Partners LLC's holdings, making the stock its 15th biggest position. Interchange Capital Partners LLC owned about 13.43% of Medicus Pharma as of its most recent SEC filing.
About Medicus Pharma
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Featured Stories
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
